Clinical Trials
5 trialsNCT00937937 2026-05-29
Dinaciclib in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02684617 2021-03-01
KEYNOTE-155
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01515176 2018-03-15
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01026324 2017-04-04
Dinaciclib in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01096342 2014-06-18
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed